Denali Therapeutics Inc. (DNLI) Return on equity 2017–2025
Denali Therapeutics Inc. (DNLI) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-50.6%FY2025 · since FY2017: -18.9% → -50.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -50.6% | -16.2 pp |
| FY2024 | -34.4% | -20.3 pp |
| FY2023 | -14.1% | +17.2 pp |
| FY2022 | -31.3% | -1.1 pp |
| FY2021 | -30.2% | -36.4 pp |
| FY2020 | 6.2% | +56.2 pp |
| FY2019 | -50.0% | -43.4 pp |
| FY2018 | -6.6% | +12.3 pp |
| FY2017 | -18.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice